Imvax Contact Us
Imvax Crunchbase Company Profile & Funding
215-485-0071 WEBCompany Type For Profit. Contact Email contact@imvax.com. Phone Number 215-485-0071. Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas …
See Also: Phone Number Preview / Show details
Henry Ford Health Doses First Patient in Combination …
WEBDETROIT (July 12, 2023) – Physicians in the Hermelin Brain Tumor Center at Henry Ford Health recently administered the first dose of IGV-001, a combination immunotherapy …
See Also: Health Preview / Show details
New, Promising Clinical Trial for Glioblastoma Starting at UNC Health
WEBNov 7, 2023 · UNC Health has a robust brain tumor research program and is currently conducting multiple clinical trials for GBM patients. The purpose of the study is to assess …
See Also: Health Preview / Show details
Imvax Announces Publication of Phase 1b Clinical Trial of IGV001 …
WEBJan 26, 2021 · Imvax ™ is an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma Multiforme (GBM) and other solid tumors …
See Also: Phone Number Preview / Show details
Imvax Announces First Patient Dosed in Phase 2b Trial of IGV001 …
(857) 244-0246 WEBMar 27, 2023 · Contacts. Thomas Stephenson. Ten Bridge Communications. [email protected]. (857) 244-0246. Imvax, Inc. today announced …
See Also: Contact Support Preview / Show details
UC enrolling patients in personalized immunotherapy …
WEBApr 13, 2023 · A total of 93 patients across up to 25 trial sites will be enrolled in the trial, with an estimated seven to 14 patients expected to enroll at UC. Patients must be newly diagnosed with GBM and have not …
See Also: Phone Number Preview / Show details
Imvax Provides Corporate Update Business Wire
WEBSeptember 06, 2023 08:00 AM Eastern Daylight Time. PHILADELPHIA-- ( BUSINESS WIRE )-- Imvax, Inc., a clinical-stage biotechnology company developing personalized, …
See Also: Tech Support Preview / Show details
Imvax to Present Preclinical Data on IGV001 Mechanism of Action …
WEBOct 21, 2021 · Imvax, Inc. today announced a poster presentation at the 36th Annual Meeting of SITC in Washington, D.C., from November 10-14, 2021. Contacts Lisa …
See Also: Contact Support Preview / Show details
Imvax Presents Data Showing Mechanisms for Broad …
WEBNovember 09, 2021 08:00 AM Eastern Standard Time. PHILADELPHIA-- ( BUSINESS WIRE )-- Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived
See Also: Tech Support Preview / Show details
Imvax to Present New Data on TumorDerived Business Wire
WEBOct 6, 2022 · Imvax, Inc. today announced two poster presentations at the 2022 Society for Immunotherapy of Cancer Meeting from November 10-12, 2022. Imvax to Present New …
See Also: Business Preview / Show details
Imvax raises $23M to advance its potential glioblastoma treatment
WEBSep 6, 2023 · Imvax intends to use proceeds from the equity financing to support the company’s ongoing mid-stage testing of its lead product candidate, IVG-001, in patients …
See Also: Support Number Preview / Show details
Philly braincancer vaccine developer tied to Jefferson raises $112 …
WEBPublished Jul. 16, 2020, 7:00 a.m. ET. Investors have pledged $112 million more to cancer developer Imvax, which plans to use the money to double its staff and upgrade a …
See Also: Phone Number Preview / Show details
Imvax Inc. Raises $112 Million in Series C Financing BioSpace
WEBJul 16, 2020 · Imvax Inc. Raises $112 Million in Series C Financing. Published: Jul 16, 2020. Funds to support Phase 2 Clinical Development of IGV-001 for treatment of …
See Also: Support Number Preview / Show details
Why is Imvax putting its new braincancer vaccine lab in Philly’s …
WEBSep 10, 2019 · To give Furey fuel to build the firm’s planned vaccine for brain cancer, Imvax plans to announce Tuesday that it has raised $40 million from a group of U.S. …
See Also: Phone Number Preview / Show details
Imvax raises $112M to advance brain cancer cell therapy
WEBJul 16, 2020 · Imvax CEO John Furey (Imvax) Imvax has raised $112 million to take its autologous tumor cell vaccine into a phase 2 glioblastoma multiforme trial. The series C …
See Also: Cell Phone Preview / Show details
Imvax Inc. Raises $112 Million in Series C Financing PR Newswire
WEBJul 16, 2020 · About Imvax, Inc. Imvax™ is a clinical-stage biotechnology company committed to revolutionizing immunotherapy for patients with devastating and intractable …
See Also: Tech Support Preview / Show details
Clinical Trial Highlight: A Phase 2b Clinical Study With a …
WEBJun 26, 2023 · Contact Us University of Cincinnati Cancer Center. 231 Albert Sabin Way, Suite 2005 Imvax 14379-201 is designed to test a personalized immunotherapy …
See Also: Contact Support Preview / Show details